Rezolute Inc
RZLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$317.76M
Close$
$1.22
73.4% downside
Current Fair Value
73.4% downsideOvervalued by 73.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $317.76 Million |
|---|---|
| Enterprise Value | $307.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.98 |
| Beta | 0.67 |
| Outstanding Shares | 104,040,292 |
Return
| Return on Equity | -69.74% |
|---|---|
| Return on Assets | -64.95% |
| Return on Invested Capital | -34.06% |
Valuation & Multiples
| P/E Ratio | -4.21 |
|---|---|
| PEG | 29.05 |
| Price to Sales | - |
| Price to Book Ratio | 4.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.67 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 10, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0806▼ 36.71% |
|---|---|
| Total Calls | 1,422,800▼ 10.61% |
| Total Puts | 114,700▼ 83.90% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.13%▼ 3.96% |
|---|---|
| Total Invested | $262.87M▲ 23.34% |
| Investors Holding | 131▼ 5.00% |
ESG Score
No data
About Rezolute Inc
23 employees
CEO: Nevan Elam Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline a...